C A Ryan

Summary

Affiliation: The Procter and Gamble Company
Country: USA

Publications

  1. ncbi Local lymph node assay (LLNA) for detection of sensitization capacity of chemicals
    G Frank Gerberick
    The Procter and Gamble Company, Central Product Safety Department, Miami Valley Innovation Center, P O Box 538707, Cincinnati, OH 45253, USA
    Methods 41:54-60. 2007
  2. ncbi Dendritic cells and skin sensitization: biological roles and uses in hazard identification
    Cindy A Ryan
    The Procter and Gamble Company, Miami Valley Innovation Center, Cincinnati, OH 45253 8707, USA
    Toxicol Appl Pharmacol 221:384-94. 2007
  3. ncbi The reduced local lymph node assay: the impact of group size
    Cindy A Ryan
    The Procter and Gamble Company, Cincinnati, OH 45253 8707, USA
    J Appl Toxicol 28:518-23. 2008
  4. ncbi Extrapolating local lymph node assay EC3 values to estimate relative sensitizing potency
    Cindy A Ryan
    The Procter and Gamble Company Cincinnati, Ohio, USA
    Cutan Ocul Toxicol 26:135-45. 2007
  5. ncbi Interactions of contact allergens with dendritic cells: opportunities and challenges for the development of novel approaches to hazard assessment
    Cindy A Ryan
    Miami Valley Innovation Center, Central Product Safety Department, The Procter and Gamble Company, Cincinnati, Ohio 45253 8707, USA
    Toxicol Sci 88:4-11. 2005
  6. ncbi Examination of a vehicle for use with water soluble materials in the murine local lymph node assay
    C A Ryan
    The Procter and Gamble Company, Miami Valley Laboratories, PO Box 538707, Cincinnati, OH 45253 8707, USA
    Food Chem Toxicol 40:1719-25. 2002
  7. ncbi Gene expression changes in peripheral blood-derived dendritic cells following exposure to a contact allergen
    Cindy A Ryan
    Miami Valley Laboratories, Central Product Safety Department, The Procter and Gamble Company, P O Box 538707, Cincinnati, OH 45253, USA
    Toxicol Lett 150:301-16. 2004
  8. ncbi Local lymph node assay: differentiating allergic and irritant responses using flow cytometry
    G F Gerberick
    Miami Valley Laboratories, The Procter and Gamble Company, Cincinnati, Ohio 45239 8707, USA
    Methods 19:48-55. 1999
  9. ncbi Contact allergenic potency: correlation of human and local lymph node assay data
    G F Gerberick
    Human and Environmental Safety Division, Procter and Gamble, Cincinnati, OH 45252, USA
    Am J Contact Dermat 12:156-61. 2001
  10. ncbi Local lymph node assay: validation assessment for regulatory purposes
    G F Gerberick
    Miami Valley Laboratory, Procter and Gamble Company, the Zeneca Central Toxicology Laboratory, Alderley Park, Cincinnati, OH 45253 8707, USA
    Am J Contact Dermat 11:3-18. 2000

Detail Information

Publications28

  1. ncbi Local lymph node assay (LLNA) for detection of sensitization capacity of chemicals
    G Frank Gerberick
    The Procter and Gamble Company, Central Product Safety Department, Miami Valley Innovation Center, P O Box 538707, Cincinnati, OH 45253, USA
    Methods 41:54-60. 2007
    ....
  2. ncbi Dendritic cells and skin sensitization: biological roles and uses in hazard identification
    Cindy A Ryan
    The Procter and Gamble Company, Miami Valley Innovation Center, Cincinnati, OH 45253 8707, USA
    Toxicol Appl Pharmacol 221:384-94. 2007
    ..This paper reports information that was presented during the Workshop...
  3. ncbi The reduced local lymph node assay: the impact of group size
    Cindy A Ryan
    The Procter and Gamble Company, Cincinnati, OH 45253 8707, USA
    J Appl Toxicol 28:518-23. 2008
    ..It is concluded that a rLLNA with two mice/group would display decreased sensitivity and is inappropriate for use in hazard identification...
  4. ncbi Extrapolating local lymph node assay EC3 values to estimate relative sensitizing potency
    Cindy A Ryan
    The Procter and Gamble Company Cincinnati, Ohio, USA
    Cutan Ocul Toxicol 26:135-45. 2007
    ..Judicious use of this approach for extrapolating EC3 values can provide information on a likely potency classification for use in risk assessment and may avoid the need for repeat animal testing...
  5. ncbi Interactions of contact allergens with dendritic cells: opportunities and challenges for the development of novel approaches to hazard assessment
    Cindy A Ryan
    Miami Valley Innovation Center, Central Product Safety Department, The Procter and Gamble Company, Cincinnati, Ohio 45253 8707, USA
    Toxicol Sci 88:4-11. 2005
    ....
  6. ncbi Examination of a vehicle for use with water soluble materials in the murine local lymph node assay
    C A Ryan
    The Procter and Gamble Company, Miami Valley Laboratories, PO Box 538707, Cincinnati, OH 45253 8707, USA
    Food Chem Toxicol 40:1719-25. 2002
    ..However, if a test material is not soluble in DMF or DMSO, or if higher test concentrations can be achieved in an aqueous vehicle, then 1% L92 may provide a better alternative to water alone in terms of improved assay performance...
  7. ncbi Gene expression changes in peripheral blood-derived dendritic cells following exposure to a contact allergen
    Cindy A Ryan
    Miami Valley Laboratories, Central Product Safety Department, The Procter and Gamble Company, P O Box 538707, Cincinnati, OH 45253, USA
    Toxicol Lett 150:301-16. 2004
    ..Additionally, it is hoped that some of the transcript changes identified through this approach will be shown to be suitable for use in the development of an in vitro predictive assay for contact sensitization...
  8. ncbi Local lymph node assay: differentiating allergic and irritant responses using flow cytometry
    G F Gerberick
    Miami Valley Laboratories, The Procter and Gamble Company, Cincinnati, Ohio 45239 8707, USA
    Methods 19:48-55. 1999
    ....
  9. ncbi Contact allergenic potency: correlation of human and local lymph node assay data
    G F Gerberick
    Human and Environmental Safety Division, Procter and Gamble, Cincinnati, OH 45252, USA
    Am J Contact Dermat 12:156-61. 2001
    ..Preclinical testing for sensitization potential is critically important for hazard assessment before human exposure. The murine local lymph node assay (LLNA) is the most recently accepted test method for sensitization hazard assessment...
  10. ncbi Local lymph node assay: validation assessment for regulatory purposes
    G F Gerberick
    Miami Valley Laboratory, Procter and Gamble Company, the Zeneca Central Toxicology Laboratory, Alderley Park, Cincinnati, OH 45253 8707, USA
    Am J Contact Dermat 11:3-18. 2000
    ....
  11. ncbi Cytokine mRNA expression in human epidermis after patch treatment with rhus and sodium lauryl sulfate
    C A Ryan
    Procter and Gamble Company, Miami Valley Laboratories, Cincinnati, OH 45253 8707, USA
    Am J Contact Dermat 10:127-35. 1999
    ..Cytokines have been shown to play a pivotal role in the development and elicitation of contact hypersensitivity reactions. The sources of these cytokines in the skin include T cells, keratinocytes, and Langerhans cells...
  12. ncbi Approaches for the development of cell-based in vitro methods for contact sensitization
    C A Ryan
    The Procter and Gamble Company, Miami Valley Laboratories, PO Box 538707, Cincinnati, OH 45253-8707, USA
    Toxicol In Vitro 15:43-55. 2001
    ....
  13. ncbi Cytokine induction of a human acute myelogenous leukemia cell line (KG-1) to a CD1a+ dendritic cell phenotype
    B C Hulette
    Procter and Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio 45253-8707, USA
    Arch Dermatol Res 293:147-58. 2001
    ..These findings illustrate that phenotypic, morphologic and functional DCs can be derived from the KG-1 cell line...
  14. ncbi Identification of gene expression changes induced by chemical allergens in dendritic cells: opportunities for skin sensitization testing
    Lucy A Gildea
    Central Product Safety Department, Miami Valley Innovation Center, The Procter and Gamble Company, Cincinnati, Ohio 45253 8707, USA
    J Invest Dermatol 126:1813-22. 2006
    ....
  15. ncbi A chemical dataset for evaluation of alternative approaches to skin-sensitization testing
    G Frank Gerberick
    The Procter and Gamble Company, Miami Valley Laboratories, Cincinnati, OH 45253 8707, USA
    Contact Dermatitis 50:274-88. 2004
    ..It is hoped that this dataset will accelerate the development, evaluation and eventual validation of new approaches to skin-sensitization testing...
  16. ncbi Compilation of historical local lymph node data for evaluation of skin sensitization alternative methods
    G Frank Gerberick
    The Procter and Gamble Company, Miami Valley Innovation Center, P O Box 538707, Cincinnati, OH 45253 8707, USA
    Dermatitis 16:157-202. 2005
    ..In addition to accurately identifying skin sensitizers, the LLNA can also provide a reliable measure of relative sensitization potency, information that is pivotal to the successful management of human health risks...
  17. ncbi Use of a B cell marker (B220) to discriminate between allergens and irritants in the local lymph node assay
    G Frank Gerberick
    The Procter and Gamble Company, Miami Valley Laboratories, P O Box 538707, Cincinnati, Ohio 4523 8707, USA
    Toxicol Sci 68:420-8. 2002
    ..25. These data demonstrate that analysis of B220 expression in DLN may be useful in differentiating between allergen and irritant responses induced in chemically treated mice...
  18. ncbi Increased number of dendritic cells in draining lymph nodes accompanies the generation of contact photosensitivity
    G F Gerberick
    Procter and Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio 45239 8707
    J Invest Dermatol 96:355-61. 1991
    ..These results suggest that application and photoactivation of TCSA induces cellular and functional changes in the lymph node DC indicative of their involvement in the induction phase of a contact photoallergic reaction...
  19. ncbi Relationship of CD86 surface marker expression and cytotoxicity on dendritic cells exposed to chemical allergen
    Ben C Hulette
    The Procter and Gamble Company, Miami Valley Laboratories, PO Box 538707, Cincinnati, OH 45253-8707, USA
    Toxicol Appl Pharmacol 209:159-66. 2005
    ....
  20. ncbi Application of the risk assessment paradigm to the induction of allergic contact dermatitis
    Susan P Felter
    The Procter and Gamble Co, Miami Valley Laboratories, 11810 E Miami River Rd, Cincinnati, OH 45061, USA
    Regul Toxicol Pharmacol 37:1-10. 2003
    ....
  21. ncbi Elucidating changes in surface marker expression of dendritic cells following chemical allergen treatment
    Ben A Hulette
    The Procter and Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio 45253, USA
    Toxicol Appl Pharmacol 182:226-33. 2002
    ....
  22. ncbi Predictive identification of human skin sensitization thresholds
    David A Basketter
    Unilever, Colworth House, Sharnbrook, Bedfordshire, UK
    Contact Dermatitis 53:260-7. 2005
    ....
  23. ncbi Preservatives and skin sensitization quantitative risk assessment
    David A Basketter
    Unilever, Colworth House, Sharnbrook, Bedfordshire, UK
    Dermatitis 19:20-7. 2008
    ....
  24. ncbi Assessment of glycosylation-dependent cell adhesion molecule 1 as a correlate of allergen-stimulated lymph node activation
    Catherine J Betts
    Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, UK
    Toxicology 185:103-17. 2003
    ....
  25. ncbi Mechanistic applicability domain classification of a local lymph node assay dataset for skin sensitization
    David W Roberts
    School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, UK
    Chem Res Toxicol 20:1019-30. 2007
    ..This understanding is necessary if reliable non-animal approaches, including (quantitative) structure-activity relationships (Q)SARs, read-across, and experimental chemistry based models, are to be developed...
  26. ncbi B220 analysis with the local lymph node assay: proposal for a more flexible prediction model
    Catherine J Betts
    Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, UK
    J Appl Toxicol 27:506-10. 2007
    ..As a result a new prediction model is proposed in which reliance on the use of absolute thresholds is reduced, and in which small changes in control values can be better accommodated...
  27. ncbi The local lymph node assay and skin sensitization: a cut-down screen to reduce animal requirements?
    Ian Kimber
    Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, UK
    Contact Dermatitis 54:181-5. 2006
    ..However, a detailed evaluation will be necessary to provide reassurance that a reduction in group size would provide adequate sensitivity across a range of skin sensitization potencies...
  28. ncbi Determination of in vivo dose response and allergen-specific T cells in subjects contact-sensitized to squaric acid dibutyl ester
    Melissa M Camouse
    University Hospitals of Cleveland Case Medical Center, Cleveland, OH, USA
    Dermatitis 19:95-9. 2008
    ..Squaric acid dibutyl ester (SADBE) is a known contact sensitizer, but dose-response data are not defined...